U.S. House and Senate health committee leaders express concern about a new FDA review pilot program because it appears designed to enable corruption and reward President Trump’s allies with faster drug approvals.
Johnson & Johnson discontinues its Auτonomy Phase 2b Alzheimer’s study after interim data showed its experimental antibody posdinemab failed to produce a statistically significant benefit.
U.S. House and Senate health committee leaders express concern about a new FDA review pilot program because it appears designed to enable corruption and reward President Trump’s allies with faster drug approvals.
Johnson & Johnson discontinues its Auτonomy Phase 2b Alzheimer’s study after interim data showed its experimental antibody posdinemab failed to produce a statistically significant benefit.
Novo Nordisk says data from two global Phase 3 trials of semaglutide (Ozempic and Wegovy) have failed to slow clinical progression in adults with early-stage symptomatic Alzheimer’s disease over two years.
FDA investigators cite Molecular PharmaGroup, an outsourcing facility in New Providence, N.J., for multiple sterility and quality-control deficiencies after a two-week inspection.
